Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
XP

WKN: A2H48J | ISIN: SE0009973563 | Ticker: 6XP
Frankfurt
18.11.26 | 15:25
0,965 Euro
-3,69 % -0,037
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XSPRAY PHARMA AB Chart 1 Jahr
5-Tage-Chart
XSPRAY PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,1621,24818.11.

Aktuelle News zur XSPRAY PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.11.XFRA CAPITAL ADJUSTMENT INFORMATION - 11.11.2026324Das Instrument 6XP SE0009973563 XSPRAY PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 11.11.2026 und ex Kapitalmassnahme am 12.11.2026 The instrument 6XP SE0009973563 XSPRAY PHARMA AB EQUITY...
► Artikel lesen
06.11.XSpray Pharma AB: Xspray Pharma publishes Interim Report for the third quarter 2026180July-September 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -39,323 thousand (-47,332) Earnings per share before dilution amounted to SEK?-0.83 (-1.25) Cash...
► Artikel lesen
06.11.XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 90 million with an over-allotment issue of approximately SEK 72 million213THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA...
► Artikel lesen
05.11.XSpray Pharma AB: Xspray Pharma notified that the FDA has commenced an inspection at NerPharMa's manufacturing facility366Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has today been informed by its contract manufacturer NerPharMa that the U.S. Food and Drug Administration (FDA) has commenced an unannounced follow-up...
► Artikel lesen
XSPRAY PHARMA Aktie jetzt für 0€ handeln
02.10.XSpray Pharma AB: Xspray Pharma provides regulatory status update for Dasynoc and Nilopki392Xspray Pharma AB (publ) today provides an update on the regulatory status for its two lead product candidates, Dasynoc and Nilopki. The Company reiterates its plan to resubmit the New Drug Applications...
► Artikel lesen
20.08.Xspray's Dasynoc approval bid foiled again by FDA's manufacturer concerns3
19.08.XSpray Pharma AB: Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc1.051The FDA's Complete Response Letter relates to the previously communicated observations at NerPharMa, concerning outstanding GMP (Good Manufacturing Practice) observations, as well as a request for additional...
► Artikel lesen
05.08.XSpray Pharma AB: Xspray Pharma Interim Report Second Quarter 2026555April-June 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -39,794 thousand (-44,885) Earnings per share before dilution amounted to SEK -0.87 (-1.21) Cash flow...
► Artikel lesen
26.06.XSpray Pharma AB: Xspray Pharma provides regulatory update on its US product candidates Nilopki and Dasynoc and notes continued progress with its third-party manufacturer NerPharMa680Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) provides an update on the FDA review of its two US new drug applications. For Nilopki®, Xspray has defined an approach to address the items raised...
► Artikel lesen
05.06.XSpray Pharma AB: Xspray Pharma Receives CRL from U.S. FDA for Nilopki477Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology platform to develop improved versions of marketed protein kinase inhibitors (PKIs)...
► Artikel lesen
03.06.XSpray Pharma AB: Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead291Xspray Pharma's two newly implemented long-term incentive programs, LTIP 2025/2028 and LTIP 2026/2029, have reached full participation from the employees to whom they were offered. Participating employees...
► Artikel lesen
12.05.XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026258The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 12 May 2026.Adoption of income statement and balance sheet for the financial...
► Artikel lesen
28.04.XSpray Pharma AB: Interim Report First Quarter 2026377January-March 2026, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -35,380 thousand (-42,321)Earnings per share before dilution amounted to SEK -0.85 (-1.14)Cash flow...
► Artikel lesen
23.04.XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue fully utilized332THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA...
► Artikel lesen
14.04.XSpray Pharma AB: FDA accepts trade name Nilopki for Xspray's drug candidate XS003 (nilotinib)892The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib...
► Artikel lesen
31.03.XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue296THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA...
► Artikel lesen
31.03.XFRA CAPITAL ADJUSTMENT INFORMATION - 31.03.2026459Das Instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY wird ex Kapitalmassnahme gehandelt am 31.03.2026 The instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY is traded ex capital adjustment...
► Artikel lesen
26.03.XSpray Pharma AB: Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased323THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA...
► Artikel lesen
24.03.XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue415THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA...
► Artikel lesen
11.03.XSpray Pharma AB: Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc - PDUFA date August 25, 2026674The U.S. Food and Drug Administration (FDA) has accepted Xspray Pharma's resubmitted New Drug Application (NDA) for Dasynoc® for review under the 505(b)(2) procedure. The FDA has set a PDUFA date of...
► Artikel lesen
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1